增强丙型肝炎病毒DNA疫苗免疫原性的策略

殷霄; 文波; 谭文杰

增强丙型肝炎病毒DNA疫苗免疫原性的策略

1. 中国疾病预防控制中心病毒病预防控制所
2. 吉林大学生命科学学院

基金项目:

国家“863”计划专题项目(2007AA02Z455)；国家传染病科技重大专项(2009ZX10004-715)；

详细信息

中图分类号: R392
计量
- 文章访问数: 3266
- HTML全文浏览量: 20
- PDF下载量: 910
- 被引次数: 0
出版历程
- 出版日期: 2011-01-20

Progress in the development and immunogenicity improvement of DNA vaccine against chronic HCV infection

Research funding:

摘要

摘要:
当前全世界有超过1.7亿慢性丙型肝炎(CHC)感染者,目前尚无有效的疫苗。最近丙型肝炎病毒(HCV)实验性疫苗的研制有不少进展。本文综述了增强HCV DNA疫苗免疫原性的策略及相关进展。
- 肝炎病毒属 /
- 疫苗,DNA /
- 免疫原性
Abstract:
More than 170 million people are currently affected by chronic hepatitis C virus (HCV) infection worldwide.Currently, there is no vaccine available.There are many HCV experimental vaccines developed and progressed recently.Here, we would discuss strategies of enhancing immunogenicity of DNA vaccine and review some progress towards development of DNA vaccine against chronic HCV infection.
- hepacivirus /
- vaccines /
- DNA

HTML全文

参考文献(23)

[1]Rehermann B, Nascimbeni M.Immunology of hepatitis B virus and hepatitis C virus infection[J].Nat Rev Immune, 2005, 5 (3) :215-229.

[2]Mannes MP, Wedemeyer H, Cornberg M.Treating viral hepatitis C:efficacy, side effects, and complications[J].Gut, 2006, 55 (9) :1350-1359.

[3]Houghton M, Abrignani S.Prospects for a vaccine against the hepatitis C virus[J].Nature, 2005, 436:961-966.

[4]Sallberg M, Frelin L, Weiland O.DNA vaccine therapy for chronic hepatitis C virus (HCV) infection:immune control of a moving target[J].Expert Opin Biol Ther, 2009, 9 (7) :805-815.

[5]Pierre L.Technological advances to increase immunogenicity of DNA vaccines[J].Vaccines, 2002, 1 (1) :85-93.

[6]Sallberg MM, Frelin L, Diepolder H, et al.A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C[C].Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver, 2009.

[7]Alvarez-Lajonchere L, Shoukry NH, Gra B, et al.Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial[J].J Viral Hepat, 2009, 16 (3) :156-167.

[8] Large MK, Kittlesen DJ, Hahn YS.Suppression of host immune response by the core protein of hepatitis C virus:possible implications for hepatitis C virus persistence[J].J Immunol, 1999, 162 (2) :931-938.临床肝胆病杂志2011年第27卷第1期

[9]Tokushige K, Wakita T, Pachuk C, et al.Expression and immune response to hepatitis C virus core DNA-based vaccine constructs[J].Hepatology, 1996, 24 (1) :14-20.

[10]Lee SW, Cho JH, Lee KJ, et al.Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses[J].Mol Cells, 1998, 8 (4) :444-451.

[11]Isaguliants MG, Petrakova NV, Mokhonov VV, et al.DNA immunization efficiently targets conserved functional domains of protease and ATPase/helicase of nonstructural 3 protein (NS3) of human hepatitis C virus[J].Immunol Lett, 2003, 88 (1) :1-13.

[12]Lang KA, Yan J, Draghia-Akli R, et al.Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine[J].Vaccine, 2008, 26 (49) :6225-6231.

[13]Jens E, Jasperzu P, Michael G, et al.Proteins of the hepatitis C virus in a response against the nonstructural cellular and humoral immune genetic immunization generates[J].J Immune, 1998, 161 (9) :4917-4923.

[14]Masalova OV, Lesnova EI, Pichugin AV, et al.The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization[J].Vaccine, 2010, 28 (8) :1987-1996.

[15]Frelin L, Alheim M, Chen A, et al.Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo[J].Gene Ther, 2003, 10 (8) :686-699.

[16]Gao M, Wang HP, Wang YN, et al.HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4 (+) Th1 cell responses in vivo[J].Vaccine, 2006, 24 (26) :5491-5497.

[17]Ma X, Forns X, Gutierrez R, et al.DNA-based vaccination against hepatitis C virus (HCV) :effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice[J].Vaccine, 2002, 20 (27-28) :3263-3271.

[18]Hong Yu, Lorne A.Babiuk, et al.Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3[J].J Gen Virol, 2004, 85:1533-1543.

[19]Frelin L, Alheim M, Chen A, et al.Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo[J].Gene Ther, 2003, 10 (8) :686-699.

[20]Ahlen G, Soderholm J, Tjelle T, et al.In Vivo Ele-ctroporation Enhances the Immunogenicity of Hepatitis C Virus Nonstructural 3/4A DNA by Increased Local DNA Uptake, Protein Expression, Inflammation, and Infiltration of CD3+T Cells[J].J Immunol, 2007, 179 (7) :4741-4753.

[21]Schwendener RA, Ludewig B, Cerny A, et al.Liposome-based vaccines[J].Methods Mol Biol, 2010, 605:163-175.

[22]Desjardins D, Huret C, Dalba C, et al.Recombinant retrov-irus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development[J].J Gene Med, 2009, 11 (4) :313-325.

[23]Folgori A, Capone S, Ruggeri L, et al.A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees[J].Nat Med, 2006, 12 (2) :190-197.

施引文献

资源附件(0)

访问统计